

11 March 2024

ASX ANNOUNCEMENT

IMEXHS SUCCESSFULLY RAISES \$1.5M VIA A PLACEMENT TO SUPPORT GROWTH

Highlights

- \$1.25 million successfully raised under the Placement, supported by new and existing institutional investors (“**Placement**”).
- Conditional placement to certain directors and their associated entities to raise \$0.25m, subject to approval by shareholders (“**Conditional Placement**”)
- Shares under the Placement and Conditional Placement (together, the “**Offer**”) to be issued at \$0.55 (“**Offer Price**”), representing a 15.4% discount to the last closing price of \$0.65 on 6 March 2024 and a 13% discount to the 5-day VWAP.
- Net proceeds of the Offer will be used to strengthen the Company’s balance sheet and drive growth with a focus on supporting new and future contracts.

IMEXHS Limited (ASX: IME) (“**IMEXHS**” or “**the Company**”) is pleased to announce that it has received binding commitments for \$1.25 million via a placement to sophisticated and institutional investors and will raise an additional \$0.25m via a Conditional Placement to IMEXHS directors and their associated entities, subject to approval by shareholders at the Company’s upcoming AGM.

IMEXHS Founder and CEO, Dr German Arango said: “We appreciate the support we have had on this raise. The funds enable us to fund growth most particularly working capital. The business is travelling well, and I am confident that we will deliver a strong result in 2024.”

Offer Details

IMEXHS will issue a total of 2,727,273 new fully paid ordinary shares (“**Shares**”) at an issue price of \$0.55 per Share to raise \$1.5 million (before costs) under the Placement and the Conditional Placement.

The Placement was well supported with strong demand from new and existing institutional and sophisticated investors. 2,272,728 shares will be issued under the Placement to raise \$1.25m.

The Offer Price represents a discount of:

- 15.4% to IMEXHS’s closing share price on 6 March 2024;
- 13.0% to the 5-day VWAP prior to the trading halt; and

Headquarter Australia

Sydney
122 O’Riordan Street MASCOT NSW 2020
enquiries@imexhs.com.au

Offices Latam

Bogotá, Colombia.
Calle 92 # 11-51, Of 202
+ 57 (1) 316 48 90
soporte@imexhs.com

Offices USA

Doral, Florida.
8200 NW 41ST. Ste. 200-41 Doral, FL 33166
admin.usa@imexhs.com

- 13.4% to 15-day VWAP prior to trading halt.

Net proceeds of the Offer will be used to strengthen the Company's balance sheet and drive growth with a focus on supporting new and future contracts.

The Shares issued under the Placement will be issued under IMEXHS's available placement capacity under ASX Listing Rule 7.1. It is anticipated that settlement of the Placement will occur on 14 March 2024 with the Shares being allotted on 15 March 2024. All new Shares will rank equally with existing Shares from their date of issue.

IMEXHS Directors have also demonstrated their continued support for the Company by committing to invest an additional \$0.25m, on the same terms as the Placement. The issue of 454,545 Shares under the Conditional Placement to IMEXHS Directors (and their associates) is subject to shareholder approval at the Company's annual general meeting expected to be held in April 2024.

Authorised for release by the Board of IMEXHS Limited.

-ENDS-

For more information, please contact:

Reena Minhas, CFO & Company Secretary

E: enquiries@imexhs.com.au

T: +61 (0)438 481 139

About IMEXHS

IMEXHS Limited (ASX: IME) is an innovative provider of medical imaging software and radiology services in 18 countries including Colombia, the US and Australia. Founded in 2012, IMEXHS develops software as a service (SaaS) imaging solutions that includes a Picture Archiving and Communications System (PACS), a Radiology Information System (RIS), a Cardiology Information System (CIS) and an Anatomical Pathology Laboratory Information System (APLIS). Its solutions are completely cloud-based, vendor neutral and zero footprint, with no need for installed software. The IMEXHS products are designed to increase productivity and save money for end users, with a scalable platform that enhances patient outcomes. For more information, visit www.imexhs.com

Important Disclaimers

Forward-Looking Statements:

Certain statements made in this release are forward-looking statements and are based on IMEXHS's current expectations, estimates and projections. Words such as "anticipates" "expects" "estimates" "forecasts" and similar expressions are intended to identify forward-looking statements. Although IMEXHS believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond IMEXHS's control. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. IMEXHS will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.

Headquarter Australia

Sydney
122 O'Riordan Street MASCOT NSW 2020
enquiries@imexhs.com.au

Offices Latam

Bogotá, Colombia.
Calle 92 # 11-51, Of 202
+ 57 (1) 316 48 90
soporte@imexhs.com

Offices USA

Doral, Florida.
8200 NW 41ST. Ste. 200-41 Doral, FL 33166
admin.usa@imexhs.com